Navidence reposted this
Let's face it: the pressure to produce RWE isn't just increasing—it's becoming a make-or-break factor for market access. In conversation with Derk earlier this year, both Matt Veatch and Aaron Kamauu MD MS MPH were unequivocal: developing a long-term RWE strategy isn't just smart—it's essential for survival in the modern pharmaceutical landscape. But here's the million-dollar question: How do we ensure the rigor of RWE studies matches that of traditional randomized controlled trials (RCTs)? Watch back on the conversation here: https://lnkd.in/euVH3Rwe Or if you're more of a reader, catch our summary blog here: https://lnkd.in/efYV2tpD